Literature DB >> 27813878

Antimalarial Drugs as Immune Modulators: New Mechanisms for Old Drugs.

Jie An1, Mark Minie2, Tomikazu Sasaki3, Joshua J Woodward4, Keith B Elkon1,5.   

Abstract

The best known of the naturally occurring antimalarial compounds are quinine, extracted from cinchona bark, and artemisinin (qinghao), extracted from Artemisia annua in China. These and other derivatives are now chemically synthesized and remain the mainstay of therapy to treat malaria. The beneficial effects of several of the antimalarial drugs (AMDs) on clinical features of autoimmune disorders were discovered by chance during World War II. In this review, we discuss the chemistry of AMDs and their mechanisms of action, emphasizing how they may impact multiple pathways of innate immunity. These pathways include Toll-like receptors and the recently described cGAS-STING pathway. Finally, we discuss the current and future impact of AMDs on systemic lupus erythematosus, rheumatoid arthritis, and devastating monogenic disorders (interferonopathies) characterized by expression of type I interferon in the brain.

Entities:  

Keywords:  Toll-like receptors; autoimmunity; cGAS; innate immunity; rheumatoid arthritis; systemic lupus erythematosus

Mesh:

Substances:

Year:  2016        PMID: 27813878     DOI: 10.1146/annurev-med-043015-123453

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  35 in total

1.  Is Inflammasome a Potential Target of Prophylaxis in Rheumatic Heart Disease?

Authors:  Teneema Kuriakose; Thirumala-Devi Kanneganti
Journal:  Circulation       Date:  2018-12-04       Impact factor: 29.690

2.  Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare.

Authors:  Juan M Mejia-Vilet; Samir V Parikh; Huijuan Song; Paolo Fadda; John P Shapiro; Isabelle Ayoub; Lianbo Yu; Jianying Zhang; Norma Uribe-Uribe; Brad H Rovin
Journal:  Nephrol Dial Transplant       Date:  2019-07-01       Impact factor: 5.992

Review 3.  Absent in Melanoma 2 proteins in SLE.

Authors:  Divaker Choubey; Ravichandran Panchanathan
Journal:  Clin Immunol       Date:  2017-01-03       Impact factor: 3.969

Review 4.  Interrupting cyclic dinucleotide-cGAS-STING axis with small molecules.

Authors:  Herman O Sintim; Clinton G Mikek; Modi Wang; Moloud A Sooreshjani
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

Review 5.  Artemisinins-a Promising New Treatment for Systemic Lupus Erythematosus: a Descriptive Review.

Authors:  Xiaozhen Mu; Chenchen Wang
Journal:  Curr Rheumatol Rep       Date:  2018-07-28       Impact factor: 4.592

6.  Lupus-Associated Immune Complexes Activate Human Neutrophils in an FcγRIIA-Dependent but TLR-Independent Response.

Authors:  Ramon G Bonegio; Jessica D Lin; Britte Beaudette-Zlatanova; Michael R York; Hanni Menn-Josephy; Kei Yasuda
Journal:  J Immunol       Date:  2019-01-04       Impact factor: 5.422

Review 7.  Artemisinin and its derivatives: a potential therapeutic approach for oral lichen planus.

Authors:  Rui-Jie Ma; Ming-Jing He; Ya-Qin Tan; Gang Zhou
Journal:  Inflamm Res       Date:  2019-02-01       Impact factor: 4.575

8.  Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.

Authors:  Paige W Wolstencroft; Livia Casciola-Rosen; David F Fiorentino
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

Review 9.  Aminoquinoline antimalarial therapy in dermatomyositis-are we missing opportunities with respect to comorbidities and modulation of extracutaneous disease activity?

Authors:  Richard D Sontheimer
Journal:  Ann Transl Med       Date:  2018-04

Review 10.  New insights into the role of antinuclear antibodies in systemic lupus erythematosus.

Authors:  David S Pisetsky; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2020-09-03       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.